HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER


Creative Commons License

Bektas M., Yuce S., Ay M., Uyar M., Onder M., Kilic M. I.

European Congress of Rheumatology (EULAR), Milan, Italy, 31 May - 03 June 2023, pp.544, (Summary Text) identifier